Multiple training interventions significantly improve reproducibility of PET/CT-based lung cancer radiotherapy target volume delineation using an IAEA study protocol

AbstractBackground and purposeTo assess the impact of a standardized delineation protocol and training interventions on PET/CT-based target volume delineation (TVD) in NSCLC in a multicenter setting.Material and methodsOver a one-year period, 11 pairs, comprised each of a radiation oncologist and nuclear medicine physician with limited experience in PET/CT-based TVD for NSCLC from nine different countries took part in a training program through an International Atomic Energy Agency (IAEA) study (NCT02247713). Teams delineated gross tumor volume of the primary tumor, during and after training interventions, according to a provided delineation protocol. In-house developed software recorded the performed delineations, to allow visual inspection of strategies and to assess delineation accuracy.ResultsFollowing the first training, overall concordance indices for 3 repetitive cases increased from 0.57±0.07 to 0.66±0.07. The overall mean surface distance between observer and expert contours decreased from −0.40±0.03cm to −0.01±0.33cm. After further training overall concordance indices for another 3 repetitive cases further increased from 0.64±0.06 to 0.80±0.05 (p=0.01). Mean surface distances decreased from −0.34±0.16cm to −0.05±0.20cm (p=0.01).ConclusionMultiple training interventions improve PET/CT-based TVD delineation accuracy in NSCLC and reduce interobserver variation

Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases

IntroductionStereotactic body radiotherapy (SBRT) is used to treat liver metastases with the intention of ablation. High local control rates were shown. Magnetic resonance imaging guided radiotherapy (MRgRT) provides the opportunity of a marker-less liver SBRT treatment due to the high soft tissue contrast. We report herein on one of the largest cohorts of patients treated with online MRgRT of liver metastases focusing on oncological outcome, toxicity, patient reported outcome measures (PROMs), quality of life.Material and methodsPatients treated for liver metastases with online MR-guided SBRT at a 1,5 T MR-Linac (Unity, Elekta, Crawley, UK) between March 2019 and December 2021 were included in this prospective study. UK SABR guidelines were used for organs at risk constraints. Oncological endpoints such as survival parameters (overall survival, progression-free survival) and local control as well as patient reported acceptance and quality of life data (EORTC QLQ-C30 questionnaire) were assessed. For toxicity scoring the Common Toxicity Criteria Version 5 were used.ResultsA total of 51 patients with 74 metastases were treated with a median of five fractions. The median applied BED GTV D98 was 84,1 Gy. Median follow-up was 15 months. Local control of the irradiated liver metastasis after 12 months was 89,6%, local control of the liver was 40,3%. Overall survival (OS) after 12 months was 85.1%. Progression free survival (PFS) after 12 months was 22,4%. Local control of the irradiated liver lesion was 100% after three years when a BED ≥100 Gy was reached. The number of treated lesions did not impact local control neither of the treated or of the hepatic control. Patient acceptance of online MRgSBRT was high. There were no acute grade ≥ 3 toxicities. Quality of life data showed no significant difference comparing baseline and follow-up data.ConclusionOnline MR guided radiotherapy is a noninvasive, well-tolerated and effective treatment for liver metastases. Further prospective trials with the goal to define patients who actually benefit most from an online adaptive workflow are currently ongoing

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

BACKGROUND Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-positive primary central nervous system (CNS) tumors. METHODS Patients with TRK fusion-positive primary CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. The primary endpoint was investigator-assessed objective response rate (ORR). RESULTS As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3-79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16-49) for all patients. In all patients, the 24-week disease control rate was 73% (95% CI: 54-87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45-100), 56% (95% CI: 38-74), and 85% (95% CI: 71-99), respectively. Median time to response was 1.9 months (range 1.0-3.8 months). Duration of treatment ranged from 1.2-31.3+ months. Treatment-related adverse events were reported for 20 patients, with Grade 3-4 in 3 patients. No new safety signals were identified. CONCLUSIONS In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile

In vivo Identification and Specificity assessment of mRNA markers of hypoxia in human and mouse tumors

<p>Abstract</p> <p>Background</p> <p>Tumor hypoxia is linked to poor prognosis, but identification and quantification of tissue hypoxia remains a challenge. The hypoxia-specificity of HIF-1α target genes in vivo has been questioned due to the confounding influence of other microenvironmental abnormalities known to affect gene expression (e.g., low pH). Here we describe a new technique that by exploiting intratumoral oxygenation heterogeneity allows us to identify and objectively rank the most robust mRNA hypoxia biomarkers.</p> <p>Methods</p> <p>Mice carrying human (FaDu_dd) or murine (SCCVII) tumors were injected with the PET hypoxia tracer FAZA. Four hours post-injection tumors were removed, frozen, and crushed into milligram-sized fragments, which were transferred individually to pre-weighed tubes containing RNAlater and then weighed. For each fragment radioactivity per tissue mass and expression patterns of selected mRNA biomarkers were analyzed and compared.</p> <p>Results</p> <p>In both tumour models, fragmentation into pieces weighing 10 to 60 mg resulted in tissue fragments with highly variable relative content of hypoxic cells as evidenced by an up to 13-fold variation in FAZA radioactivity per mass of tissue. Linear regression analysis comparing FAZA retention with patterns of gene expression in individual tissue fragments revealed that CA9, GLUT1 and LOX mRNA levels were equally and strongly correlated to hypoxic extent in FaDu_dd. The same link between hypoxia and gene expression profile was observed for CA9 and GLUT1, but not LOX, in SCCVII tumors. Apparent in vivo hypoxia-specificity for other putative molecular markers of tissue hypoxia was considerably weaker.</p> <p>Conclusions</p> <p>The portrayed technique allows multiple pairwise measurements of mRNA transcript levels and extent of hypoxia in individual tumors at a smallest possible volumetric scale which (by limiting averaging effects inherent to whole-tumor analysis) strengthen the conclusiveness on true hypoxia-specificity of candidate genes while limiting the required number of tumors. Among tested genes, our study identified CA9, GLUT1 and possibly LOX as highly specific biomarkers of tumor hypoxia in vivo.</p

Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1)

Background: The higher specificity of amino-acid positron emission tomography (AA-PET) in the diagnosis of gliomas, as well as in the differentiation between recurrence and treatment-related alterations, in comparison to contrast enhancement in T1-weighted MRI was demonstrated in many studies and is the rationale for their implementation into radiation oncology treatment planning. Several clinical trials have demonstrated the significant differences between AA-PET and standard MRI concerning the definition of the gross tumor volume (GTV). A small single-center non-randomized prospective study in patients with recurrent high grade gliomas treated with stereotactic fractionated radiotherapy (SFRT) showed a significant improvement in survival when AA-PET was integrated in target volume delineation, in comparison to patients treated based on CT/MRI alone. Methods: This protocol describes a prospective, open label, randomized, multi-center phase II trial designed to test if radiotherapy target volume delineation based on FET-PET leads to improvement in progression free survival (PFS) in patients with recurrent glioblastoma (GBM) treated with re-irradiation, compared to target volume delineation based on T1Gd-MRI. The target sample size is 200 randomized patients with a 1:1 allocation ratio to both arms. The primary endpoint (PFS) is determined by serial MRI scans, supplemented by AA-PET-scans and/or biopsy/surgery if suspicious of progression. Secondary endpoints include overall survival (OS), locally controlled survival (time to local progression or death), volumetric assessment of GTV delineated by either method, topography of progression in relation to MRIor PET-derived target volumes, rate of long term survivors (> 1 year), localization of necrosis after re-irradiation, quality of life (QoL) assessed by the EORTC QLQ-C15 PAL questionnaire, evaluation of safety of FET-application in AA-PET imaging and toxicity of re-irradiation. Discussion: This is a protocol of a randomized phase II trial designed to test a new strategy of radiotherapy target volume delineation for improving the outcome of patients with recurrent GBM. Moreover, the trial will help to develop a standardized methodology for the integration of AA-PET and other imaging biomarkers in radiation treatment planning. Trial registration: The GLIAA trial is registered with ClinicalTrials.gov (NCT01252459, registration date 02.12.2010), German Clinical Trials Registry (DRKS00000634, registration date 10.10.2014), and European Clinical Trials Database (EudraCT-No. 2012-001121-27, registration date 27.02.2012)

A Simulation-based Decision Support System to Improve Healthcare Facilities Performance – Elaborated on an Irish Emergency Department

Emergency departments (EDs) are a crucial access point to the healthcare system in Ireland. High patient demand and limited resources have resulted in long waiting times and long lengths of stay in EDs. Some of this pressure on EDs could be ameliorated by more streamlined hospital processes particularly in managing discharges and managing the volume of work. This research sought to develop a simulation-based Decision Support System (DSS) to enable an accelerated development of a simulation based solution to improve quality and care at Irish hospitals. In order to investigate causes of bottlenecks and insufficient distribution of resources, a novel process modelling approach is developed, where patient pathways are investigated in relation to the work flow of medical staff with the consideration of the dependence on limited resources. This approach is included in the simulation based DSS which aids to consult managers of EDs by providing a comprehensive perspective onto the crucial factors affecting their services and processes. To prove this novel concept of Multiple Participants Pathway Modelling (MPPM) with regard to Flexible Resource Allocation (FRA), a simulation study is applied to the ED of an academic teaching hospital in Dublin. This research is divided into primary and secondary research phases, in which the secondary – the applied field work – is guided by a combination of qualitative and quantitative research methodologies. EDs are an ideal test environment as they represent a dynamic working environment where the allocation of medical staff is flexible and tailored to current patient demand. However, exact medical procedures must still be followed. These factors are considered by the application of MPPM with regard to FRA. These complex process interactions form a holistic simulation process flow network allowing application of scenarios that impact both process flow pathways: those of patients and of medical staff. This research makes a contribution to both theory and practice: the theory is covered by the framework which outlines the simulation based DSS, while the practical objectives are delivered by its application in the ED. The investigated scenarios offer a higher degree of confidence in the interpretation of the simulation results and provide a clearer picture of the resulting consequences of the potential introduction of certain policies

Combined Liver- Small Bowel Transplantation

Nach Transplantation moduliert die Leber nicht nur die Immunantwort des Empfängers gegenüber ihr selbst, sondern übt auch auf mittransplantierte Organe einen protektiven Effekt aus. Dieses Phänomen wurde in der vorliegenden Arbeit an dem hoch immunogenen Dünndarm untersucht. Diese Studie war dabei nicht nur unter immunologischen Gesichtspunkten von Bedeutung. So stellt die simultane Leber- / Dünndarmtransplantation für Patienten, die an einer Leberzirrhose infolge eines Kurzdarmsyndrom leiden, eine erfolgversprechende Therapieoption dar. Zur experimentellen Analyse dieser speziellen Transplantationsform existierte aber in der Ratte bisher kein vergleichbares Modell. In der vorliegenden Arbeit wird daher erstmalig ein Modell etabliert, in dem – orientiert an den Verhältnissen beim Menschen – Leber (arterialisiert) und Dünndarm simultan und orthotop transplantiert werden. Mittels kurzfristiger Immunsuppression wurde bei allogener Transplantation hier nicht nur Akzeptanz sondern Toleranz erreicht und mittels Indikator-Herz- und Hauttransplantation überprüft. Die dazu benötigte immunsuppressive Dosis unterschritt dabei die für eine erfolgreiche isolierte Dünndarmtransplantation notwendige Immunsuppression erheblich. Dieser Toleranzentwicklung geht eine zeitlich begrenzte Abstoßungsreaktion voraus. Die daran beteiligten zellulären Mechanismen wurden durch sequentielle Immunhistologie dargestellt. Während dieser Abstoßung sammeln sich überdurchschnittlich viele apoptotische T-Lymphozyten, hauptsächlich CD8+ Zellen, im Lebertransplantat, nicht aber im transplantierten Dünndarm an. Dieses Phänomen konnte mittels einer neu etablierten Doppelfärbung dargestellt werden. Apoptoseinduktion in alloreaktiven T-Zellen könnte einer der Mechanismen sein, die den immunsuppressiven Effekt des Lebertransplantates erklären und den gleichzeitig transplantierten Dünndarm vor seiner Abstoßung bewahren.Following transplantation, the liver modifies not only the immune response of the recipient towards herself but also protects a co-transplanted organ against rejection. Using a rat transplantation model and performing combined liver-/ small bowel transplantation, this phenomenon was investigated in this study. Currently, the simultaneous transplantation of those two organs is the only available treatment for patients with liver cirrhosis after short bowel syndrome. Up until now, no sufficient experimental animal model representing this specific situation was existing. In our study we were able to establish for the first time such a model – where liver and small bowel are transplanted simultaneously and into orthotopic positions. By using short term immunosuppression allogeneic transplantation we were able to achieve not only acceptance but tolerance to the grafts. This was proven by indicator heart and skin transplantation. The necessary dosage of immunosuppressive agents was significantly lower then the dosage used in isolated small bowel transplantation. Previous to tolerance, a limited rejection crisis took place. This process was analysed by immunohistological staining of the involved cell populations. During this rejection crisis we found an accumulation of apoptotic lymphocytes (mainly CD8+) in the transplanted liver but not in the simultaneously transplanted small bowel. This phenomenon was further analysed with a newly established double staining method. The induction of apoptotic cell death in alloreactive T-cells within the liver graft could be a possible mechanism explaining the immunoprotective effect of the liver transplant towards the simultaneously transplanted small bowel

Application of Discrete-Event Simulation in Health Care: a Review

The acceptance of applying process simulation in health care has significantly increased during the last decade, leading to an increase of publication in this area. Health care managers and researchers that are attracted by the idea of applying simulation in their field, desire to view methodologies and results of different simulation projects, yet may be overstrained by the large volume of the diverse literature. Thus, this paper, structured as a quick reference guide, presents a comprehensive review of process simulation applications in healthcare areas, which summarises projects applied in health care facilities like hospitals, emergency departments, intensive care units, surgical procedures, outpatient clinics, and facilities allocated in the health care supply chain. Additionally the provision of health in economic simulation models is covered within this review. Seventy articles are reviewed covering a range of the last decade that present the potential of simulation as a strategic competitive tool for decision makers in the aforementioned areas. Challenges to implement simulation results into existing systems are also discussed